V1RH10 Inhibitors
V1RH10 inhibitors encompass a diverse array of compounds that exert their inhibitory effects through various biochemical pathways, ultimately leading to a decrease in V1RH10's functional activity. For instance, inhibitors such as Palmitoyl-DL-carnitine and Oligomycin act on the energy production mechanisms in cells; Palmitoyl-DL-carnitine disrupts fatty acid oxidation, while Oligomycin impairs the ATP synthase function, both leading to reduced acetyl-CoA and ATP availability, which are crucial for V1RH10 activity. Additionally, compounds such as 2,4-Dinitrophenol (DNP) decrease ATP levels by uncoupling oxidative phosphorylation, further constrainingV1RH10's functional activity. Similarly, Genistein and Wortmannin target signaling pathways by inhibiting tyrosine kinases and phosphoinositide 3-kinases (PI3K), respectively, which could be integral for V1RH10's post-translational modification or downstream signaling. Rapamycin and LY294002 also disrupt the PI3K/Akt/mTOR pathway, potentially impacting V1RH10's regulation or expression.
Furthermore, chemical inhibitors such as Alisertib, Paclitaxel, and Tunicamycin interfere with cell cycle progression, microtubule stability, and protein glycosylation, respectively. Each of these mechanisms can play a role in the modulation of V1RH10's function or stability. For instance, V1RH10's activity may be tied to cell cycle phases, and thus, the action of Alisertib and Paclitaxel can lead to its functional inhibition. Tunicamycin's inhibition of N-linked glycosylation could destabilize V1RH10 if glycosylation is essential for its structure or activity. Additionally, Cycloheximide and Brefeldin A target protein synthesis and trafficking; Cycloheximide halts protein synthesis on ribosomes, potentially reducing V1RH10 levels, while Brefeldin A disrupts protein trafficking, which could affect V1RH10's cellular localization and function. These inhibitors collectively demonstrate the multifaceted approaches by which V1RH10's activity can be diminished through direct and indirect interactions with specific biochemical pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Oligomycin | 1404-19-9 | sc-203342 sc-203342C | 10 mg 1 g | $146.00 $12250.00 | 18 | |
Oligomycin is an inhibitor of the ATP synthase (complex V of the mitochondrial electron transport chain). By inhibiting ATP synthase, oligomycin reduces the production of ATP, which is essential for the energy-dependent functions of V1RH10. | ||||||
2,4-Dinitrophenol, wetted | 51-28-5 | sc-238345 | 250 mg | $58.00 | 2 | |
DNP uncouples oxidative phosphorylation by carrying protons across the mitochondrial membrane, leading to a decrease in ATP production. The reduced ATP levels negatively impact the energy-dependent processes in which V1RH10 is involved. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can impede signaling pathways reliant on tyrosine phosphorylation, which may be crucial for the post-translational modification of V1RH10, thereby reducing its functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, wortmannin disrupts the PI3K/Akt pathway which could lead to decreased phosphorylation and activation of downstream targets, including V1RH10. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin) which is a central regulator of cell growth and metabolism. V1RH10 activity may be dependent on mTOR signaling for its functional regulation or expression levels. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor that prevents activation of the PI3K/Akt pathway. By blocking this pathway, it could indirectly reduce the activity of V1RH10 if V1RH10 is a downstream effector. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora kinase A inhibitor, which interferes with the cell cycle progression. If V1RH10 is involved in cell cycle regulation or its activity is modulated during the cell cycle, inhibition of Aurora kinase A could negatively impact V1RH10 function. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules and inhibits their disassembly, which can arrest cells in the G2/M phase of the cell cycle. As a result, if V1RH10 is involved in cell cycle progression, its activity could be hindered by paclitaxel. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin blocks N-linked glycosylation by inhibiting the enzyme dolichyl-phosphate N-acetylglucosaminephosphotransferase. If V1RH10 requires glycosylation for its stability or function, tunicamycin could indirectly lead to its inhibition. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in protein synthesis on ribosomes. If V1RH10 synthesis is actively occurring, cycloheximide would lead to decreased expression and activity. | ||||||